Cellectis (CLLS) Reports Q2 Loss of EUR0.23/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results
September 8, 2016 5:31 PM EDT- First patient dosed in phase 1 clinical trial for UCART19
- UCART 123 manufacturing ongoing
- Strong cash position of $300 million1 (270 million) as of June 30, 2016
- Revenues and other income of $20 million2 (18 million) in the 2nd quarter of 2016
- Adjusted income attributable to shareholders3 of $9 million2 (8 million) in the 2nd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a... More
